Chinese Bird Flu Vaccine For Humans Clears Phase II Trials (China)
This article was originally published in PharmAsia News
Executive Summary
Sinovac Biotech said its bird flu vaccine for use in humans has passed Phase II clinical trials without affecting any of the 402 participants. Zhang Jiansan, vice-general manager of the Beijing-based firm, said the test results indicate the vaccine could offer several choices for treatment. The executive also said the nation is capable of producing an appropriate quantity of the vaccine should it be needed. Zhang said the company was able to control the dosage and immunity procedure for the vaccine during the trials, adding to enhanced scientific and effective methods for combating the disease. (Click here for more
You may also be interested in...
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.
GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health
Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.